Last reviewed · How we verify
Japanese Encephalitis Vaccine
At a glance
| Generic name | Japanese Encephalitis Vaccine |
|---|---|
| Also known as | Boryung Cell-Culture Japanese Encephalitis Vaccine, IXIARO Japanese Encephalitis Vaccine, ChimeriVax™-JE, Ixiaro, IXIARO |
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (PHASE1, PHASE2)
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) (PHASE4)
- Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
- Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis (PHASE4)
- Flavivirus Cross-priming Potential of IMOJEV (NA)
- Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas (PHASE4)
- A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. (PHASE3)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Japanese Encephalitis Vaccine CI brief — competitive landscape report
- Japanese Encephalitis Vaccine updates RSS · CI watch RSS
- Novartis portfolio CI